Sarepta Therapeutics (AB3A) Hedge Fund Trading Activity
Trend: ▲ Hedge Funds Increased Holdings by 4.1M Shares Last Quarter
Hedge Fund Holdings in AB3A
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
| Follow | |||||||
|---|---|---|---|---|---|---|---|
 Scott Kapnick | Highbridge Capital Management LLC | New | 100.00% | $8,608,000 | 0.27% | ||
 Charles Davidson | Wexford Capital LP | New | 100.00% | $99,960 | 0.02% | ||
 Ray Dalio | Bridgewater Associates, LP | Reduced | -20.36% | $6,037,823 | 0.02% | ||
 John Hussman | Hussman Strategic Advisors Inc | Reduced | -25.00% | $1,355,760 | 0.33% | ||
 Edward A Mule | Silver Point Capital L.P. | Sold Out | -100.00% | $5,988,542 | 0.00% |
FAQ
Which hedge funds hold Sarepta Therapeutics?
The hedge funds that hold the most shares in Sarepta Therapeutics are Scott Kapnick, Ray Dalio and John Hussman.
Are hedge funds buying or selling DE:AB3A?
In the last quarter hedge funds have Increased their holdings in Sarepta Therapeutics by 4.1M shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Sarepta Therapeutics stock?
Warren Buffet currently does not own shares in Sarepta Therapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here
